Hostname: page-component-74656f9884-8r8nv Total loading time: 0 Render date: 2026-11-08T09:23:16.113Z Has data issue: false hasContentIssue false

Initial studies on mechanism of action and cell death of active N-oxide-containing heterocycles in Trypanosoma cruzi epimastigotes in vitro

Published online by Cambridge University Press:  27 January 2014

DIEGO BENÍTEZ
Affiliation:
Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Universidad de la República, Montevideo, Uruguay
GABRIELA CASANOVA
Affiliation:
Unidad de Microscopía Electrónica de Transmisión, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
GONZALO CABRERA
Affiliation:
Facultad de Medicina, Programa de Biología Celular y Molecular, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile
NORBEL GALANTI
Affiliation:
Facultad de Medicina, Programa de Biología Celular y Molecular, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile
HUGO CERECETTO*
Affiliation:
Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Universidad de la República, Montevideo, Uruguay
MERCEDES GONZÁLEZ*
Affiliation:
Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Universidad de la República, Montevideo, Uruguay
*
* Corresponding authors: Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Universidad de la República, Iguá 4225, 11400 Montevideo, Uruguay. E-mail: megonzal@fq.edu.uy and hcerecetto@cin.edu.uy
* Corresponding authors: Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Universidad de la República, Iguá 4225, 11400 Montevideo, Uruguay. E-mail: megonzal@fq.edu.uy and hcerecetto@cin.edu.uy
Rights & Permissions [Opens in a new window]

Summary

Chagas disease, endemic in 21 countries across Latin America, kills more people in the region each year than any other parasite-borne disease. Therapeutic options have problems ranging from toxicity, poor efficacy, drug resistance and high cost. Thus, cheaper and less toxic treatments are necessary. From our in-house chemical library of agents against Trypanosoma cruzi the most relevant N-oxide-containing heterocycles were selected for mode of action and type of death studies. Also included in these studies were two active nitrofuranes. Epimastigotes of T. cruzi were used as the biological model in this study. The metabolic profile was studied by 1H NMR in association with the MTT assay. Excreted catabolites data, using 1H NMR spectroscopy, showed that most of the studied N-oxides were capable of decreasing both the release of succinate and acetate shedding, the compounds therefore possibly acting on mitochondria. Only quinoxalines and the nitrofurane Nf1 showed significant mitochondrial dehydrogenase inhibitions, but with different dose–time profiles. In the particular case of quinoxaline Qx2 the glucose uptake study revealed that the integrity of some pathways into the glycosome could be affected. Optic, fluorescence (TUNEL and propidium iodide) and transmission electron microscopy (TEM) were employed for type of death studies. These studies were complemented with 1H NMR to visualize mobile lipids. At low concentrations none of the selected compounds showed a positive TUNEL assay. However, both quinoxalines, one furoxan and one benzofuroxan showed a necrotic effect at high concentrations. Curiously, one furoxan, Fx1, one benzofuroxan, Bfx1, and one nitrofurane, Nf1, caused a particular phenotype, with a big cytoplasmatic vacuole being observed while the parasite was still alive. Studies of TEM and employing a protease inhibitor (3-methyladenine) suggested an autophagic phenotype for Bfx1 and Nf1 and a ‘BigEye’ phenotype for Fx1.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2014 
Figure 0

Fig. 1. Chemical structures of the compounds herein studied: N-oxide-containing heterocycles (Fx1, Fx2, Fx3, Bfx1, Bfx2, Qx1, Qx2), Nifurtimox (Nfx) and nitrofurane (Nf1).

Figure 1

Fig. 2. Percentage of the end products excreted by T. cruzi epimastigote Y strain to the milieu expressed with respect to untreated parasites.

Figure 2

Fig. 3. Catabolites excreted by parasites treated with compounds Qx1 (a) and Qx2 (b). Dose–response studies.

Figure 3

Fig. 4. Relevant regions of the 1H NMR spectra for the assayed excreted-catabolites. (a), (c) and (e) Untreated-parasites; (b), (d) and (f) Parasites treated with Fx2, Qx1 and Qx2 at its IC50, respectively. For experimental details see Materials and methods section. All the spectra were recorded in D2O at 295·16 K. Relevant changes in catabolite concentrations are highlighted.

Figure 4

Fig. 5. Mitochondrial dehydrogenases inhibition by Qx1 (●), Qx2 (▲) and Nf1 (■). The enzymatic activities were determined at 90 min of incubation. For experimental details see Materials and methods.

Figure 5

Table 1. Mitochondrial dehydrogenase activities, as a percentage of untreated parasites, in live parasites treated with the studied N-oxides and reference compounds

Figure 6

Table 2. Changes in the visible mobile lipids of T. cruzi treated with the different studied compounds analysed by 1H NMR

Figure 7

Fig. 6. TUNEL assays (left, DAPI-staining; centre, FITC-staining; right, phase contrast; 1000×). (a) Treatment with Bfx1 (72 μm, 24 h); (b) Treatment with Nf1 (19·5 μm, 48 h); (c) Positive control (H2O2: 500 μm, 30 min of incubation at 28 °C).

Figure 8

Fig. 7. Examples of results from the TUNEL and PI-staining assays (Up: left, DAPI-staining; centre, FITC-staining; right, phase contrast; 1000×. Down: left, PI-staining; right, phase contrast; 400×). (a) Treatment with Qx1 (8 μm, 24 h); (b) Treatment with Qx2 (18 μm, 3 h).

Figure 9

Fig. 8. Light microscopy (640×). (a) Treatment with Fx1 (50 μm, 24 h); (b) Treatment with Bfx1 (65 μm, 24 h); (c) Treatment with Nf1 (5·1 μm, 24 h). Notes: epimastigotes of T. cruzi Tulahuen 2 strain; the arrows show the cytoplasmic vacuole.

Figure 10

Fig. 9. Transmission electron microscopy of parasites treated with Fx1. (a) 12 000×; (b) Detail of (a) (40 000×); (c) Detail of (b) (200 000×). Note: big arrow: plasmatic membrane; small arrows: double membrane of vesicle.

Figure 11

Fig. 10. Transmission electron microscopy of parasites treated with Nf1. (a) 25 000×; (b) Detail of (a) (100 000×); (c) Detail of (b) (150 000×); (d) Detail of (c) (200 000×). Note: big arrow: plasmatic membrane; small arrows: double membrane of vesicle.

Figure 12

Fig. 11. Transmission electron microscopy of parasites treated with Bfx1. (a) 15 000×; (b) Detail of (a) (30 000×); (c) Detail of (b) (100 000×); (d) Detail of (b) (150 000×). Note: arrows: double membrane of vesicle.

Figure 13

Fig. 12. Pre-incubation of Bfx1-, Nf1-, and Fx1-treated epimastigotes with protease inhibitor 3-MA. Data represent the mean±s.d. of at least three independent experiments. (*) P<0·003; (**) P<0·0003.

Supplementary material: File

Benítez Supplementary Material

Table S1 and Figure S1

Download Benítez Supplementary Material(File)
File 87.4 KB